SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the November 22 FDA decision on Capricors deramiocel application for Duchenne muscular dystrophy; the company says its application is in final review and has reaffirmed confidence in the therapy. Traders broadly read managements comments and launch preparations as encouraging, while others emphasize that approval is uncertain and a rejection remains possible, fueling debate over the binary event and short positioning.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles Q3 results are driving attention, with a revenue beat and first-ever positive adjusted EBITDA prompting bullish reactions around its Quake AI data-center business. Traders are debating whether the results outweigh concerns about cash burn, financing needs and possible delays to planned capacity, while some speculate high short interest could amplify moves.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists quarterly results and outlook are driving attention, with traders focused on the new Samsung and Micron licensing revenue and managements hint that SK Hynix could be a future licensing partner. The reaction is divided: bullish traders emphasize recurring revenue and improving profitability, while others point to the earnings miss against published expectations, weaker product sales, and the post-earnings decline; the SK Hynix deal remains speculation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis weaker-than-expected Q3 results and 2026 revenue outlook have focused attention on its limited, uneven commercial traction. Bears question the valuation and favor competing quantum companies, while bulls point to technical progress and long-term potential and anticipate a rebound or short squeeze.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compasss COMP360 NDA progress and the potential expedited FDA review for treatment-resistant depression dominate discussion, with traders focused on the path to a possible 2027 launch. Sentiment is divided between confidence in Compasss clinical data and commercial infrastructure and concern that Usonas reported psilocybin filing could erode its first-mover advantage, contributing to sharp price volatility.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,959,453.18587388 with 16,959,453.64420722 in circulation. The last known price of Zcash is 1,033.61575403 USD and is down -11.66 over the last 24 hours. It is currently trading on 670 active market(s) with $1,322,935,861.71 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention after a sharp pullback following a major rally, with traders debating whether the decline reflects broader crypto weakness, liquidations, or a deeper unwind; no single cause is established. Bulls are buying the dip and pointing to Zcashs privacy focus and NU7 upgrade, while bears warn of further downside.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kuras quarterly update and earnings call are drawing attention for continued KOMZIFTI launch growth and increasing prescriptions, prompting bullish reactions about patient retention and commercial traction. Traders are also debating whether Kuras position can withstand competition from Johnson & Johnsons menin inhibitor, with some voicing concern about a stock offering.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports alleging a connection between Jensen Huangs personal conduct and a possible Chinese intelligence risk have fueled debate over Nvidias leadership and national-security exposure; the claims remain unproven. Traders are divided between seeing further downside and buying the rebound, while Bairds downgrade and concerns about AI spending visibility add to the uncertainty despite confidence in ongoing chip demand.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected quarterly results and raised outlook, alongside robust AI-compute demand and a financing plan emphasizing customer prepayments over unsecured debt, sparked a sharp rebound. Traders welcomed the update and discussed potential short covering, while skeptics questioned whether growth can overcome heavy debt, interest costs and capital spending.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

AMPXs quarterly results are driving attention: traders point to strong revenue growth, expanding margins and higher guidance, while the per-share loss and weaker EBITDA fueled a selloff. The discussion is split between buyers calling the drop an overreaction and skeptics focused on continued losses and near-term volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +120.00% and +16.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

• Reported GAAP EPS of $0.02 down -66.67% YoY
• Reported revenue of $83.9M down -10.72% YoY
• Adaptive Biotechnologies raised full year 2026 MRD revenue guidance to $276M to $286M, from $268M to $278M, and expects operating expenses of approximately $350M.

Adaptive Biotechnologies reported lower total and Immune Medicine revenue, lower adjusted EBITDA and net income versus prior-year quarters, and submitted a MolDX assessment seeking an additional Medicare maintenance-testing bundle.

Adaptive Biotechnologies reported MRD revenue growth and higher clonoSEQ test volume; NCCN established a dedicated MRD framework, the first myeloma cure definition emerged, and Q3 delivered adjusted EBITDA and free cash flow.

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Adaptive Biotechnologies Corp

Bullish Sentiment

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Stocktwits Polls

$ADPT Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.02 down -66.67% YoY
• Reported revenue of $83.9M down -10.72% YoY
• Adaptive Biotechnologies raised full year 2026 MRD revenue guidance to $276M to $286M, from $268M to $278M, and expects operating expenses of approximately $350M.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADPT Adaptive Biotechnologies Corp

Fundamentals

Latest ADPT News